Article Text

Download PDFPDF
Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6
  1. R P Hasserjian1,
  2. J Howard2,
  3. A Wood2,
  4. K Henry1,
  5. B Bain3
  1. 1Department of Histopathology, Hammersmith Hospitals NHS Trust, Du Cane Road, London W12 0NN, UK
  2. 2Department of Haematology, Hammersmith Hospitals NHS Trust
  3. 3Department of Haematology, St Mary's Hospital NHS Trust, Praed St, London W2 1NY, UK
  1. Dr Hasserjian r.hasserjian{at}ic.ac.uk

Abstract

Aims—Classic erythroleukaemia (acute myeloid leukaemia M6, or M6 AML) is defined as an excess of myeloblasts in an erythroid predominant background. Leukaemia variants in which the primitive blast cells are demonstrably erythroid are extremely rare and poorly characterised. Variably referred to as “true erythroleukaemia” or “acute erythremic myelosis”, they are often included within the M6 AML category even though they do not meet strict criteria for this type of AML.

Methods— Two cases of acute erythroid neoplasia are presented with clinical, morphological, immunophenotypic, and cytogenetic analysis.

Results—Both patients presented with profound anaemia, one in a setting of long standing myelodysplasia. Bone marrow examination revealed a predominant population of highly dysplastic erythroid cells in both cases. In one case, the liver was infiltrated by neoplastic erythroid cells. Both patients died within four months of diagnosis.

Conclusions—This report illustrates that cases of acute leukaemia occur in which the dominant neoplastic cell is a primitive erythroid cell without an accompanying increase in myeloblasts. This does not preclude the neoplastic clone originating in a multipotent haemopoietic stem cell, as suggested by cases arising in patients with myelodysplasia. Acute erythremic myelosis should be recognised as a distinct variant of M6 AML.

  • erythroleukaemia
  • erythremic myelosis
  • Di Guglielmo
  • acute leukaemia

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes